Proposed model of acquired resistance to ABT-199 in experimental models of human and mouse lymphoma. Mutations in the BH3 domain of BCL2 abolish ABT-199 binding and thus block apoptosis. Mutation in BAX transmembrane domain prevents mitochondrial translocation of BAX and thus impedes apoptosis.